The causal role of LDL-cholesterol in atherosclerotic cardiovascular disease
Short animation detailing the role of LDL-cholesterol in the development of disease and the clinical sequalae associated with disease progression.
Hear from the experts
Experts share their perspectives on “lower is better and lowest is best.”
Elevated LDL-C leads to cardiovascular disease (CVD), the number one cause of death globally. 5,6
In the US, CVD accounts for one in three deaths.3,4,5 One-third of deaths from CVD occur prematurely in people under 70 years of age.6
The WHO estimates heart disease deaths will increase 26% by 2030.7
of very high-risk patients did not meet a guideline-recommended LDL-C target2
patients with ASCVD in the U.S. don’t reach their LDL-C goals despite taking a statin10
patients with ASCVD in the U.S. are not on any lipid lowering therapy10
High low-density lipoprotein cholesterol (LDL-C) has been treatable for decades, but something is not working. Atherosclerotic cardiovascular disease continues to increase. Guideline LDL-C targets are not met. Patients give up on their medicines entirely. The problem? Patients’ needs are not being met by their cholesterol medicines.
In a recently published analysis, the US prevalence of ASCVD in 2019 was estimated at > 24 million patients. The authors noted that 72.6% of subjects with ASCVD had an LDL-C greater than the national guideline recommendation of less than 70 mg/dL. In these same subjects, only one in four were on a high-intensity statin, and over 40% were not on any lipid lowering therapy.10
Data suggest that statins cause more side effects in women than in men.7, 8, 9
Many patients who do everything right – the hard work of changing their diet, exercising and taking their medicine as prescribed – still don’t reach their goals.
- ZS Associates primary and secondary research, Sep-Oct 2018. Primary research N = 350 healthcare practitioners
- Yan AT, Yan RT, Tan M, et al. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119(8):676-683.
- Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation. 2019;139:00–00.
- World Health Organization. Cardiovascular diseases (CVDs) fact sheet. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed October 14, 2020.
- World Health Organization. The challenge of cardiovascular disease – quick statistics. https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/data-and-statistics. Accessed November 30, 2020.
- Global Status Report on Noncommunicable Diseases 2014. Geneva, Switzerland: World Health Organization; 2014. http://apps.who.int/iris bitstream/10665/148114/1/9789241564854_eng.pdf. Accessed January 11, 2021.
- Culver AL, Ockene IS, Balasubramanian R et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch. Int. Med. 172(2), 144–152 (2012).
- Barbara H Roberts & Rita F Redberg (2013) Gender disparity in statin response: are statins less effective in women?, Clinical Lipidology, 8:2, 161-163, DOI: 10.2217/ clp.13.7
- Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195–2207 (2009)
- Gu et al. Lipid treatment status and goal attainment among patients with atherosclerotic cardiovascular disease in the United states. A 2019 update. Am J Prev Cardiol. 2022 Jun; 10: 100336.